MX2012014301A - Inhibidores macrociclicos de serina proteasa de hepatitis c. - Google Patents

Inhibidores macrociclicos de serina proteasa de hepatitis c.

Info

Publication number
MX2012014301A
MX2012014301A MX2012014301A MX2012014301A MX2012014301A MX 2012014301 A MX2012014301 A MX 2012014301A MX 2012014301 A MX2012014301 A MX 2012014301A MX 2012014301 A MX2012014301 A MX 2012014301A MX 2012014301 A MX2012014301 A MX 2012014301A
Authority
MX
Mexico
Prior art keywords
protease inhibitors
serine protease
present
hepatitis
macrocyclic hepatitis
Prior art date
Application number
MX2012014301A
Other languages
English (en)
Inventor
Brian E Green
Keith F Mcdaniel
Jason P Shanley
Yat Sun Or
Yonghua Gai
Jorge Gandarilla
Dennie S Welch
Albert W Kruger
Hai-Ju Chen
Russell D Cink
Guoqiang Wang
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of MX2012014301A publication Critical patent/MX2012014301A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención se refiere a nuevos compuestos macrocíclicos y a métodos para el tratamiento de una infección por el virus de la hepatitis C, en un sujeto que necesite tal tratamiento con dichos compuestos macrocíclicos. La presente invención además se refiere a composiciones farmacéuticas que comprenden los compuestos de la presente invención o sales, ésteres o profármacos farmacéuticamente aceptables de los mismos, en combinación con un vehículo o excipiente farmacéuticamente aceptable.
MX2012014301A 2010-06-07 2011-06-07 Inhibidores macrociclicos de serina proteasa de hepatitis c. MX2012014301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39710310P 2010-06-07 2010-06-07
PCT/US2011/039397 WO2011156337A2 (en) 2010-06-07 2011-06-07 Macrocyclic hepatitis c serine protease inhibitors

Publications (1)

Publication Number Publication Date
MX2012014301A true MX2012014301A (es) 2013-04-29

Family

ID=45098613

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014301A MX2012014301A (es) 2010-06-07 2011-06-07 Inhibidores macrociclicos de serina proteasa de hepatitis c.

Country Status (8)

Country Link
US (2) US8748374B2 (es)
EP (1) EP2576564A4 (es)
JP (1) JP2013528217A (es)
CN (1) CN103025736B (es)
CA (1) CA2801584A1 (es)
MX (1) MX2012014301A (es)
TW (1) TW201211046A (es)
WO (1) WO2011156337A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014301A (es) 2010-06-07 2013-04-29 Enanta Pharm Inc Inhibidores macrociclicos de serina proteasa de hepatitis c.
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
MA37992B1 (fr) 2012-10-19 2018-09-28 Bristol Myers Squibb Co Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c.
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
CN104163851B (zh) * 2013-05-20 2019-03-05 湘北威尔曼制药股份有限公司 氟代的α-羰基类HCV NS3/4A丝氨酸蛋白酶抑制剂
JP6762873B2 (ja) 2013-09-11 2020-09-30 エモリー・ユニバーシテイ ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11472778B2 (en) * 2017-06-20 2022-10-18 University Of Massachusetts Hepatitis C virus NS3/4A protease inhibitors
US11834515B2 (en) 2017-10-11 2023-12-05 Cornell University Macrocyclic compounds as proteasome inhibitors
CN110981820B (zh) * 2019-12-25 2023-05-19 上海彩迩文生化科技有限公司 一种酸性条件下合成喹喔啉-2-酮的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010375A (es) * 2000-04-19 2003-04-25 Schering Corp Inhibidores macrociclicos de la ns3-serina proteasa del virus de la hepatitis c que comprenden porciones alquil y arilalanina p2.
EP1590442A4 (en) * 2003-02-07 2007-07-18 Enanta Pharm Inc MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
GB0612423D0 (en) * 2006-06-23 2006-08-02 Angeletti P Ist Richerche Bio Therapeutic agents
AR061629A1 (es) * 2006-06-26 2008-09-10 Enanta Pharm Inc Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c. proceso de obtencion y composiciones farmaceuticas
WO2009073719A1 (en) * 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Quinoxalinyl derivatives
JP2013505952A (ja) * 2009-09-28 2013-02-21 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新しい大環状阻害剤
TW201119667A (en) * 2009-10-19 2011-06-16 Enanta Pharm Inc Bismacrocyclic compounds as hepatitis C virus inhibitors
MX2012014301A (es) 2010-06-07 2013-04-29 Enanta Pharm Inc Inhibidores macrociclicos de serina proteasa de hepatitis c.
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors

Also Published As

Publication number Publication date
TW201211046A (en) 2012-03-16
CN103025736B (zh) 2016-07-06
US8748374B2 (en) 2014-06-10
JP2013528217A (ja) 2013-07-08
CA2801584A1 (en) 2011-12-15
WO2011156337A2 (en) 2011-12-15
EP2576564A4 (en) 2014-01-22
US9493506B2 (en) 2016-11-15
US20140287992A1 (en) 2014-09-25
WO2011156337A3 (en) 2012-04-26
EP2576564A2 (en) 2013-04-10
US20120101031A1 (en) 2012-04-26
CN103025736A (zh) 2013-04-03

Similar Documents

Publication Publication Date Title
MX2012014301A (es) Inhibidores macrociclicos de serina proteasa de hepatitis c.
MX2013007698A (es) Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
MX2013007677A (es) Inhibidores macrociclicos de serina proteasa de hepatitis.
MY159820A (en) Macrocyclic hepatitis c serine protease inhibitors
MX2018013668A (es) Inhibidores de virus de hapatitis c.
IN2014MN02652A (es)
IN2014MN02657A (es)
IN2014MN02658A (es)
UA116616C2 (uk) Інгібітори hcv серинової протеази, отримані з макроциклічного проліну
HK1166788A1 (es)
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
IN2014CN02806A (es)
MX2012008221A (es) Inhibidores de virus flaviviridae.
MX2012008211A (es) Inhibidores de virus flaviviridae.
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
IN2012DN01855A (es)
IN2011CH03893A (es)
UA103054C2 (en) Macrocyclic hepatitis c serine protease inhibitors
NZ625532A (en) Compositions and methods for treating hepatitis c virus

Legal Events

Date Code Title Description
FG Grant or registration